A Registry Study on HIV-related Lymphoma

Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group

Retrospective und prospective registry on HIV-associated lymphoma. Data on characteristics, type and toxicity of treatment and outcome of patients with HIV-lymphoma will be collected.

To study characteristics, treatment approaches and outcome of HIV-infected patients with malignant lymphoma in the combination antiretroviral therapy (cART) era. HIV-infected persons diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma will be included. The choice of treatment is not specified by the registry study. However, the type of antineoplastic treatment should follow national or international recommendations and guidelines. Data will be pseudonymized by the data manager of the treating institution. Central data management is located at Red Cross Hospital Munich, Germany.

Inclusion Criteria:

• Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma
• HIV-infection at time of lymphoma diagnosis
• Lymphoma diagnosis since 01.01.2010
• Adult patients ≥ 18 years
• Written informed consent

Exclusion Criteria:

• HIV-diagnosis > 3 months after the diagnosis of malignant lymphoma
• Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)